Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Mangoceuticals (MGRX) EBITDA Margin (2023 - 2025)

Mangoceuticals' EBITDA Margin history spans 3 years, with the latest figure at 8953.45% for Q3 2025.

  • For Q3 2025, EBITDA Margin fell 763524.0% year-over-year to 8953.45%; the TTM value through Sep 2025 reached 4142.63%, down 393361.0%, while the annual FY2024 figure was 1294.42%, 102995.0% down from the prior year.
  • EBITDA Margin for Q3 2025 was 8953.45% at Mangoceuticals, down from 3133.98% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 1929.93% in Q4 2023 and bottomed at 8953.45% in Q3 2025.
  • The 3-year median for EBITDA Margin is 1594.02% (2024), against an average of 2258.41%.
  • The largest annual shift saw EBITDA Margin surged 143491bps in 2024 before it plummeted -763524bps in 2025.
  • A 3-year view of EBITDA Margin shows it stood at 1929.93% in 2023, then tumbled by -183bps to 1594.02% in 2024, then tumbled by -462bps to 8953.45% in 2025.
  • Per Business Quant, the three most recent readings for MGRX's EBITDA Margin are 8953.45% (Q3 2025), 3133.98% (Q2 2025), and 4440.0% (Q1 2025).